In vivo 19F MR imaging and spectroscopy for the BNCT optimization.

Area of Science:

• Biomedical Imaging
• Pharmacokinetics
• Oncology

Background:

• Boron neutron capture therapy (BNCT) requires precise delivery of boron-containing agents.
• 4-borono-2-fluorophenylalanine (19F-BPA) is a promising agent for BNCT.
• In vivo evaluation of 19F-BPA biodistribution and pharmacokinetics is crucial for treatment optimization.

Purpose of the Study:

• To evaluate the in vivo boron biodistribution and pharmacokinetics of 19F-BPA.
• To correlate findings from 19F MRI and 19F MRS for optimal treatment timing.
• To assess the effect of L-DOPA on 19F-BPA tumor uptake.

Main Methods:

• In vivo 19F Magnetic Resonance Imaging (19F MRI) of rat brain.
• In vivo 19F Magnetic Resonance Spectroscopy (19F MRS) on blood samples.
• C6 glioma rat model for tumor uptake studies.
• Administration of 19F-BPA and L-DOPA.

Main Results:

• Correlation between 19F MRI and 19F MRS confirmed maximum 19F-BPA uptake in C6 glioma at 2.5 hours post-infusion.
• This finding establishes the optimal irradiation time for BNCT.
• 19F MRI indicated L-DOPA's potential to enhance 19F-BPA tumor intake.

Conclusions:

• The study successfully determined the optimal timing for 19F-BPA administration in a glioma model.
• 19F MRI and 19F MRS are effective tools for evaluating 19F-BPA pharmacokinetics in vivo.
• L-DOPA shows potential as an enhancer for 19F-BPA tumor uptake, warranting further investigation.